Bispecific Antibodies Progression in Malignant Melanoma

The discovery of oncogenes and immune checkpoints has revolutionized the treatment of melanoma in the past 10 years. However, the current PD-L1 checkpoints lack specificity for tumors and target normal cells expressing PD-L1, thus reducing the efficacy on malignant melanoma and increasing the side e...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Juan, Gong, Youling, Ma, Xuelei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984188/
https://www.ncbi.nlm.nih.gov/pubmed/35401191
http://dx.doi.org/10.3389/fphar.2022.837889

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984188/
https://www.ncbi.nlm.nih.gov/pubmed/35401191
http://dx.doi.org/10.3389/fphar.2022.837889

Ejemplares similares